Healthcare Industry News: atherosclerosis
News Release - November 24, 2010
Marvin Slosman Appointed President of Itamar-Medical Inc., North America
FRANKLIN, Mass.--(Healthcare Sales & Marketing Network)-- Itamar-Medical Inc., the leader in non-invasive ambulatory sleep testing & vascular health diagnostics, announced the hiring of Marvin Slosman as President of Itamar-Medical for North America.Marvin brings 25 years of executive experience in the medical device industry, including leadership roles with GE Healthcare and Cordis/J&J as well as a number of successful early stage growth companies. His wealth of experience in launching breakthrough technologies to the medical market, including his most recent involvement in growing several med-tech, early stage startups into thriving and successful enterprises, provides Itamar the leadership necessary to achieve our growth objectives. Marvin is multi-talented with medical experience in the areas of cardiovascular health, diagnostic imaging, and integrated hospital delivery networks.
“With the recent CPT code announcement formally recognizing the virtues of WatchPAT, coupled with increased clinical demand for our EndoPAT diagnostic on endothelial function, we envision a growing need to meet consumer and marketplace demands. Marvin brings precisely the skill set we seek to grow our North American business,” said Dr. Dov Rubin, President and CEO Itamar-Medical Ltd. “He will be an integral part of planning and executing our company strategy as we evolve in the years ahead.”
“Itamar Medical is perfectly positioned for tremendous growth in both segments of the market, delivering value to both physicians and patients with the PAT™ (Peripheral Arterial Tone) technology. The opportunity is truly revolutionary to improve the standard of care delivered through this innovative yet practical solution,” said Marvin Slosman.
About Itamar Medical
Itamar Medical Ltd. is a publicly-traded medical technology company (TASE: ITMR) utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to both the cardiovascular and autonomic nervous systems.
WatchPAT™, the most convenient, portable sleep testing device on the market, is easily installed by the patient in the comfort of their own home with over 250,000 tests worldwide. It is the only portable device providing Apnea-Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), and Oxygen Desaturation Index (ODI) based on actual sleep time and sleep states (REM/Wake/Deep/Light) without a cumbersome nasal cannula or belt around the chest. This gives the patient greater comfort, more natural sleep, as well as an amazingly low failure rate.
Itamar-Medical is the developer of the EndoPAT, the only non-invasive, FDA-cleared device intended for use in diagnosing endothelial dysfunction - an important state in the development and progress of atherosclerosis affecting both early and late stage of the disease.
For more information, visit www.itamar-medical.com.
Source: Itamar-Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!